evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,018 questions · 3,100 findings · 369 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 774 · 25%GRADE not reported 108 · 3.5%Very low 727 · 23.5%Low 840 · 27.1%Moderate 474 · 15.3%High 177 · 5.7%

Benralizumab 30 mg vs placebo

Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (high certainty).

1 finding from 1 review

Benralizumab 100 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 100 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 100 mg vs placebo

Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg leads to lower rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).

1 finding from 1 review

Targeted or adjustable individualized fortification vs standard non‐individualized fortification

Retinopathy of prematurity · promoting growth and development in very low birth weight infants receiving human milk

It is very uncertain whether targeted or adjustable individualized fortification changes retinopathy of prematurity, any compared with standard non‐individualized fortification (very low certainty).

1 finding from 1 review

Intervention not reported

Minor adverse events** ‒short‐term (> 2 weeks but ≤ 3 months) Minor adverse events provided as the proportion of patients reporting any untoward medical occurrence after an epidural injection without hospitalisations. · lumbosacral radicular pain

It is very uncertain whether the intervention changes minor adverse events** ‒short‐term (> 2 weeks but ≤ 3 months) Minor… (very low certainty).

1 finding from 1 review

Topical antibiotics with steroids vs topical steroid

Minor adverse events not leading to withdrawal of treatment · people with eczema

It is very uncertain whether topical steroid plus topical antibiotic changes minor adverse events not requiring withdrawal from treatment compared with topical steroid (very low certainty).

1 finding from 1 review